Moderna chief medical officer gives a glimpse of study results to Jerulslem post. Oct 25 2020.
Our vaccine creates antibodies in the body... which means that besides being a preventative vaccine, our product can also be used as treatment for people who've already been infected. We've shown that the product prevents the virus from replicating and improves the patient's condition," Zaks told Globes, adding that he would be "very surprised if the vaccine doesn't work."
Jerusalem Post Health & Science
Moderna's chief medical officer explains why their vaccine is better
By TOBIAS SIEGAL OCTOBER 25, 2020 02:06
Tal Zaks (photo credit: Courtesy)
Tal Zaks
(photo credit: Courtesy)
Moderna was the first company to enter clinical trials. It is expected to reveal the results of its recent comprehensive trial in the upcoming month.
Advertisement
Moderna’s chief medical officer, Tal Zaks, gave an interview to Globes earlier this week and explained why he believes that the company's vaccine for coronavirus will be better than the one being developed by Pfizer, Moderna's biggest competitor at this point.
Moderna, a relatively young American start-up, was the first company to enter clinical trials. It is expected to reveal the results of its recent comprehensive trial in the upcoming month.
Pfizer wasn't late to follow and is expected to publish its results shortly before Moderna does, possibly during October or early November. If one of these potential vaccines pans out, our lives might start returning to normal in about a year or so.
"Our vaccine creates antibodies in the body... which means that besides being a preventative vaccine, our product can also be used as treatment for people who've already been infected. We've shown that the product prevents the virus from replicating and improves the patient's condition," Zaks told Globes, adding that he would be "very surprised if the vaccine doesn't work."
Advertisement
Zaks shared with Globes what led him to join Moderna in the first place.
After completing his studies at Ben-Gurion University in Beersheba, Zaks aspired to become a children's oncologist. "Alongside my job as a physician I was also working on my doctoral thesis, and so I had the opportunity of working at the American National Cancer Institute (NCI)... Those were terrific three years, but I felt like I excelled more as a physician rather than a researcher."
He recalls thinking about focusing more on applied research, only to later realize that "the translation of science into medicine happens in the industry." That realization led him to Sanofi, a global bio-pharmaceutical company, where he was made senior vice-president and head of oncology.
"During my time at Sanofi I kept examining new technologies that could have a real impact in the world of medicine," Zaks said. "When I encountered Moderna's platform, which used RNA in order to create medicine and various vaccines, it was an offer that I couldn't resist."
"To Meirav, my wife, it seemed like an exaggerated risk. Leaving a vice-president position in a big company to work for a start-up? To me it made perfect sense, thanks to the technology and capability of translating potential into reality in such a short time."
EXPLAINING WHAT makes Moderna's platform so effective, Zaks said that "our technological infrastructure is a molecule called mRNA... That molecule enters a cell and can basically create any protein we want it to. It can be an antibody for an infectious disease, a missing protein as part of a genetic disease or a protein that encourages the creation of blood cells."